Join
Live feed
·
INSIDERFilingvia Quantisnow
Avenue Therapeutics Inc. logo

SEC Form 4: Invagen Pharmaceuticals, Inc. sold $2,999,882 worth of shares (388,888 units at $7.71), closing all direct ownership in the company

ByQuantisnow·Wall Street's wire, on your screen.
ATXI· Avenue Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATXI (Avenue Therapeutics Inc.) and more on Quantisnow.